• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Determinants of use of oral complementary-alternative medicine among women with early breast cancer:  a focus on cancer-related fatigue
ConclusionOne-in-four patients reported use of OCAM. More severe CRF was consistently associated with its use. Moreover, older, better educated, wealthier, more anxious women, and those receiving chemotherapy seemed more prone to use OCAM. Characterizing profiles of BC patients more frequently resorting to OCAM may help deliver targeted information about its benefits and potential risks.
Source: Breast Cancer Research and Treatment - September 24, 2021 Category: Cancer & Oncology Source Type: research

The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials
The objective of this systematic review will be to evaluate the comparative efficacy and safety of pharmacological and non-pharmacological treatments in children and adolescents with ADHD. Methods Searches involving PubMed/MEDLINE and the Cochrane Database of Systematic Reviews will be used to identify related systematic reviews and relevant randomized trials. Search results will be supplemented by reports from the regulatory and health technology agencies, clinical trials registers and by data requested from trialists and/or pharmaceutical companies. We will consider studies eva...
Source: Systematic Reviews - February 27, 2015 Category: Global & Universal Source Type: research

Prescription of Complementary and Alternative Medicine (CAM) in an Italian Cohort of Pediatric Headache Patients (P03.115)
CONCLUSIONS: Our study shows that CAM is widely used among pediatric headache patients, and physicians are mostly unaware of prescription. Further studies are required to investigate safety and efficacy of CAM, as a possible side-medicine to conventional pharmacological approach.Disclosure: Dr. Colombo has nothing to disclose. Dr. Dalla Libera has nothing to disclose. Dr. Pavan has nothing to disclose. Dr. Comi has received personal compensation for activities with Novartis, Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., Merck Serono, and Bayer Schering.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Colombo, B., Dalla Libera, D., Pavan, G., Comi, G. Tags: P03 Headache: Epidemiology Source Type: research